Enoxaparin and bleeding complications: A review in patients with and without renal insufficiency

被引:130
作者
Gerlach, AT
Pickworth, KK
Seth, SK
Tanna, SB
Barnes, JF
机构
[1] Ohio State Univ, Med Ctr, Dept Pharm, Columbus, OH 43210 USA
[2] Boston Med Ctr, Dept Pharm, Boston, MA USA
[3] Med Univ S Carolina, Dept Pharm Serv, Charleston, SC 29425 USA
来源
PHARMACOTHERAPY | 2000年 / 20卷 / 07期
关键词
D O I
10.1592/phco.20.9.771.35210
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Study Objective. To compare the frequency of bleeding complications from enoxaparin in patients with normal renal function versus patients with renal insufficiency. Design. Retrospective chart review. Setting. University-based tertiary care center. Patients. One hundred six patients who received two or more doses of enoxaparin. Measurements and Main Results. Total bleeding complications occurred in 22% of patients with normal renal function and 51% with renal insufficiency (p<0.01). Major bleeds were also significantly different, 2% and 30%, respectively (p<0.001). No patients with normal renal function were given fresh-frozen plasma or packed red blood cells, whereas in those with renal insufficiency 13% and 32%, respectively received these products (p<0.01). Conclusion. Enoxaparin may have resulted in increased bleeding complications and use of blood products in patients with renal insufficiency. Prospective studies need to be conducted to define the drug's role and dosage adjustments in these patients.
引用
收藏
页码:771 / 775
页数:5
相关论文
共 12 条
  • [1] Monitoring of low-molecular-weight heparins in cardiovascular disease
    Abbate, R
    Gori, AM
    Farsi, A
    Attanasio, M
    Pepe, G
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 1998, 82 (5B) : 33L - 36L
  • [2] Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction - Results of the thrombolysis in myocardial infarction (TIMI) 11B trial
    Antman, EM
    McCabe, CH
    Gurfinkel, EP
    Turpie, AGG
    Bernink, PJLM
    Salein, D
    de Luna, AB
    Fox, K
    Lablanche, JM
    Radley, D
    Premmereur, J
    Braunwald, E
    [J]. CIRCULATION, 1999, 100 (15) : 1593 - 1601
  • [3] Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement
    Bergqvist, D
    Benoni, G
    Bjorgell, O
    Fredin, H
    Hedlundh, U
    Nicolas, S
    Nilsson, P
    Nylander, G
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (10) : 696 - 700
  • [4] DELAYED ELIMINATION OF ENOXAPARINE IN PATIENTS WITH CHRONIC RENAL-INSUFFICIENCY
    CADROY, Y
    POURRAT, J
    BALADRE, MF
    SAIVIN, S
    HOUIN, G
    MONTASTRUC, JL
    VERNIER, I
    BONEU, B
    [J]. THROMBOSIS RESEARCH, 1991, 63 (03) : 385 - 390
  • [5] A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease
    Cohen, M
    Demers, C
    Gurfinkel, EP
    Turpie, AGG
    Fromell, GJ
    Goodman, S
    Langer, A
    Califf, RM
    Fox, KAA
    Premmereur, J
    Bigonzi, F
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (07) : 447 - 452
  • [6] FAREED J, 1998, AM J CARDIOL, V82, P31
  • [7] A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma
    Geerts, WH
    Jay, RM
    Code, KI
    Chen, EL
    Szalai, JP
    Saibil, EA
    Hamilton, PA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (10) : 701 - 707
  • [8] Heparin and low-molecular-weight heparin - Mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety
    Hirsh, J
    Warkentin, TE
    Raschke, R
    Granger, C
    Ohman, EM
    Dalen, JE
    [J]. CHEST, 1998, 114 (05) : 489S - 510S
  • [9] Isselbaher KJ, 1994, HARRISONS PRINCIPLES, P1265
  • [10] *RHON POUL ROR PHA, 1998, LOV